Key points are not available for this paper at this time.
Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Antonio González-Martı́n
Bhavana Pothuri
Ignace Vergote
New England Journal of Medicine
Cornell University
University of Pennsylvania
McGill University
Building similarity graph...
Analyzing shared references across papers
Loading...
González-Martı́n et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d77af93fae90fd6048f479 — DOI: https://doi.org/10.1056/nejmoa1910962